INTRODUCTION {#s1}
============

Tumor hypoxia promotes invasiveness and is associated with resistance to chemotherapeutics and radiation and thus poor prognosis \[[@R1]--[@R5]\]. Human carbonic anhydrase IX (CA IX) shows limited expression in normal tissues \[[@R6]\] and is significantly up-regulated by hypoxia-inducible factor 1α (HIF-1α) \[[@R7]\] or other alternative microenvironmental factors \[[@R8]--[@R12]\] in a variety of tumors. CA IX is crucial for cancer cell survival because bicarbonate and protons, produced upon CA IX-catalyzed reversible hydration of CO~2~, are necessary to maintain the cellular pH balance: bicarbonate is transported into the cell to neutralize intracellular acid, while protons increase extracellular acidification \[[@R13]--[@R16]\]. CA IX also stimulates cell spreading and epithelial-mesenchymal transition \[[@R17], [@R18]\]. Therefore, CA IX has been proposed to be a promising tumor hypoxia biomarker for diagnostic and targeted drug delivery applications \[[@R19]\].

Sulfonamides are classical CA inhibitors, where the deprotonated sulfonamide group is required for displacement of the catalytic Zn^2+^-bound water molecule to bind directly with Zn^2+^ in the active site to inhibit CA \[[@R20], [@R21]\]. Therefore, the binding affinity can be enhanced using inhibitors with the lowered p*K~a~* of the sulfonamide group \[[@R21], [@R22]\]. Introduction of fluorine atoms that lower the p*K~a~* due to their electron-withdrawing capabilities is one of the choices due to unique features, such as high electronegativity, small size, low atomic weight, and contribution to increased lipophilicity. Fluorine is found in \~20% of current pharmaceuticals and this trend is increasing \[[@R23]\]. Krishnamurthy and colleagues investigated fluorinated benzensulfonamides and concluded that fluorine is the best choice for electron-withdrawing substituents \[[@R21]\]. We expanded this strategy and created new routes for functionalization of pentafluorobenzensulfonamides \[[@R24], [@R25]\] including *para*-, *ortho*-, and *meta*- substituted fluorinated benzensulfonamides. The bulky hydrophobic groups at *ortho* or *meta* positions are necessary for the favorable hydrophobic contacts with the amino acids of CA IX binding pocket \[[@R26]\]. Here we present novel the *ortho*-substituted fluorinated benzenesulfonamides VR16-09 and VR16-10 (Table [1](#T1){ref-type="table"}, Scheme [1](#F6){ref-type="fig"}) in combination with the previously chemically and biophysically characterized *meta* and *ortho*-substituted fluorinated inhibitors VD11-4-2 and VD12-09 \[[@R26]\]. We hypothesized that these benzenesulfonamides will exhibit high affinity and strong selectivity towards recombinant CA IX and will possess significant functional effects in cancer cell lines on reducing hypoxia-induced acidosis as well as hypoxia-dependent clonogenic survival, providing efficacious opportunity to target CA IX-expressing cells.

![Synthesis scheme of VR16-09 and VR16-10\
Reagents and conditions: (a) NH~3~ aq, THF, --10° C; (b) 7, Et~3~N, MeOH, r.t. 24 h, then conc. HCl; (c~1~) cyclododecylamine, Et~3~N, DMSO, 70° C, 36 h, then H~2~O, HCl; (c~2~) cyclooctylamine, Et~3~N, DMSO, 70° C, 24 h, then H~2~O, HCl; (d) CH~3~COCl, AlCl~3~, CH~2~Cl~2~, 0° C -- +2° C, then conc. HCl; (e) NaOH, H~2~O, dioxane, Br~2~, 0° C -- +2° C, then conc. HCl, (f) NH~2~CSNH~2~, H~2~O, reflux 3 h, then NaOH 1 h reflux, then 2M HCl.](oncotarget-09-26800-g006){#F6}

###### The dissociation constants (*K*~*d*~s) of VR16-09, VR16-10, VD11-4-2, and VD12-09 for 12 recombinant catalytic domains of human active CA isoforms as determined by FTSA at pH 7.0 (37° C)

            *K~d~* (*K~i~*), nM                               
  --------- --------------------- ---------------- ---------- ----------
  CA I      ≥200 000              5000             710        50 000
  CA II     ≥200 000              1000             60         1 300
  CA III    ≥200 000              ≥200 000         40 000     ≥200 000
  CA IV     ≥200 000              1820             25         1 700
  CA VA     ≥200 000              5000             2 500      3 300
  CA VB     45000                 100              5.6        210
  CA VI     ≥200 000              26300            95         4 300
  CA VII    37 000                100              9.8        330
  CA IX     **0.16** (\<1)        **0.20** (\<1)   **0.05**   **1.1**
  CA XII    710 (100)             370              3.3        330
  CA XIII   20                    40               3.6        140
  CA XIV    170                   170              1.6        170

The *K~i~* values determined by SFA (pH 7.5, 25^°^ C) are shown in the parentheses. Uncertainties of FTSA and SFA measurements do not exceed 2-fold.

^\*^*K~d~* values of VD11-4-2 and VD12-09 towards CA isoforms have been already published \[[@R26]\].

RESULTS AND DISCUSSION {#s2}
======================

Binding and inhibition of recombinant CA isoforms {#s2_1}
-------------------------------------------------

The affinities of VR16-09 and VR16-10 to 12 catalytically active recombinant CA isoforms were determined by the fluorescent thermal-shift assay (FTSA) and compared with previously published \[[@R26]\] inhibitors VD11-4-2 and VD12-09 (Table [1](#T1){ref-type="table"}). The *K~i~* values against CA IX and CA XII were also measured by the stopped-flow inhibition assay (SFA) of the CO~2~ hydration CA enzymatic activity (Table [1](#T1){ref-type="table"}). FTSA revealed that VR16-09 bound CA IX significantly (*K~d~* = 0.16 nM) stronger than other CA isoforms (*K~d~*s \> 200 μM) (Table [1](#T1){ref-type="table"}, Figure [1A--1C](#F1){ref-type="fig"}). VR16-09 with the bulky aminocyclododecyl group exhibited greater selectivity towards CA IX as compared with VR16-10, VD12-09, and VD11-4-2 bearing aminocyclooctyl groups. SFA did not allow the determination of *K~i~* \< \~2 nM against CA IX, because the concentration of CA IX was 10 nM, thus limiting the determination of *IC~50~* at 5 nM. Therefore, the *K~d~*s determined by the FTSA should be used rather than SFA. Nevertheless, SFA confirmed that VR16-09 and VR16-10 efficiently inhibited the CA IX activity (Figure [1D--1F](#F1){ref-type="fig"}). These compounds are advantageous compared to SLC-0111 that has entered the clinical trials (*K~i(CA\ IX)~* = 45 nM, *K~i(CA\ XII)~* = 4.5 nM and only 20-fold selectivity over CA II, thus would possibly exhibit larger adverse effects \[[@R27], [@R28]\]). In contrast, selectivity of VR16-09 for CA IX over CA I and CA II is more than one million-fold.

![The binding affinity by FTSA (panels **A**--**C**) and inhibition by SFA (panels **D**--**F**) of VR16-09 towards human recombinant CAs. Thermal melting curves of 8 μM CA IX (A) and 5 μM CA II (B) determined by ANS fluorescence in the presence of various VR16-09 concentrations. (C) Melting temperatures (*T~m~*) of CA IX (■), CA II (◊) and CA XII (▲) as a function of added compound concentration. The lines were regressed according to \[[@R60]\]. Absorbance decrease due to enzymatic acidification of the medium by CA IX (D) or CA XII (E) for various VR16-09 concentrations. (F) Fraction inhibition of CA IX (■) or CA XII (▲) as a function of the total VR16-09 concentration. The lines are fit according to the Morrison equation \[[@R50]\].](oncotarget-09-26800-g001){#F1}

Crystal structures of inhibitors bound to recombinant CA IX {#s2_2}
-----------------------------------------------------------

The structures of the CA IX catalytic domain in complex with VR16-09 (PDB ID: 6G98), VR16-10 (PDB ID: 6G9U), VD12-09 (PDB ID: 6FE0) and VD11-4-2 (PDB ID: 6FE1) were determined by X-ray crystallography at resolutions ranging from 1.75 Å to 2.47 Å (Figure [2](#F2){ref-type="fig"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The sulfonamide moiety and trifluorobenzene cycle of all observed ligands fit in the conserved region of the CA IX active site, the cycloalkane tail moieties were guided towards the hydrophobic part of the active site and moieties with terminal hydroxyl group were located in the hydrophilic part of the active site. The sulfonamide amino group formed a coordination bond with Zn(II), as observed in many other CA-sulfonamide complexes. All ligands were positioned very similarly within the active site of CA IX, except with some differences occurring in the case of VD11-4-2 (Figure [2](#F2){ref-type="fig"}). VD11-4-2 also formed two additional hydrogen bonds with Asn62 and Gln92, which might explain its stronger affinity for CA IX as compared to other analyzed compounds. All four crystal structures showed that some conformational changes have occurred in the CA IX active site pocket as compared to other known CA IX structures \[[@R29], [@R30]\]. In order to fully understand conformational changes occurring in those cases, we also determined apo (ligand free) CA IX structure at 1.87 Å resolution (PDB ID: 6FE2). In case of VR16-09, the cyclododecyl moiety altered rotamer of Gln92, which in turn changed the conformation of Gln67 (Figure [2](#F2){ref-type="fig"}).

![Crystal structure of VR16-09 (panel **A**, PDB ID: 6G98) bound in the active site of human recombinant CA IX. The F~o~ − F~c~ omit map is contoured at 3σ. (Panel **B**) shows that VR16-09 fitted in apo-CA IX structure (PDB ID: 6FE2), demonstrating collision points with residues indicating too short inter-atomic distances if conformational changes had not occurred. Protein and ligand carbons are shown in green and black, respectively, and apo-CA IX residues are shown in light blue. Atom colors are: oxygen (red), nitrogen (blue), fluorine (light blue), and sulfur (yellow). (Panel **C**) shows comparison of binding modes for compounds VR16-09 (black carbons), VR16-10 (green carbons), VD12-09 (yellow carbons), and VD11-4-2 (light blue carbons). The zinc ion is shown as a gray sphere and residues participating in hydrogen bonds or charged interactions are also specified for the respective inhibitors. The figure was prepared using Pymol \[[@R61]\].](oncotarget-09-26800-g002){#F2}

CA IX-dependent functional activities of inhibitors in cancer cells {#s2_3}
-------------------------------------------------------------------

Compounds were evaluated for their biological functional activities in a panel of human cancer cell lines. CA IX expression was increased in hypoxic (0.2% O~2~) A549 (lung), AsPC-1 (pancreatic), MDA-MB-231 (breast), H460 (lung), and HeLa (cervical) cancer cells, whereas CA XII expression was similar under normoxia and hypoxia ([Supplementary Figures 1, 2](#SD1){ref-type="supplementary-material"}). We evaluated the potency of the compounds to inhibit the CA catalytic activity in hypoxic MDA-MB-231 cells by determining the rate of the CO~2~/HCO~3~^-^ hydration/dehydration reaction via ^18^O depletion from ^13^C^18^O~2~, measured by mass-spectrometric (MS) gas analysis. Addition of cell suspension resulted in an acceleration of the reaction, indicating CA catalytic activity in MDA-MB-231 cells (Figure [3A](#F3){ref-type="fig"}). Pre-incubation of the cell suspension with VR16-09, VD11-4-2, or VD12-09 resulted in a dose-dependent decrease in CA activity (Figure [3B--3D](#F3){ref-type="fig"}). To verify the CA IX specificity, hypoxic HeLa cells, in which CA IX was knocked out (KO) ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}), were exposed to VR16-09, VD11-4-2 and VD12-09 at concentrations of near maximum inhibition of extracellular CA activity in hypoxic MDA-MB-231 cells. In both HeLa CA IX KO lines, VR16-09 (300 nM), VD11-4-2 (300 nM), or VD12-09 (30 μM) did not alter CA activity (Figure [3E](#F3){ref-type="fig"}), although considerable CA activity remained, indicating activity of other CA isoforms. In HeLa wild-type (WT) cells, CA activity decreased (*P \<* 0.01) to 30--40%, values that did not significantly differ from the two HeLa CA IX KO cell lines. Thus, VR16-09, VD11-4-2, and VD12-09 specifically target CA IX, while other CAs remain unaffected. Previously Frost and colleagues reported a *K~i~* value of 85.3 nM against extracellular CA for the fluorescent sulfonamide Cpd 5c in intact hypoxic MDA-MB-231 cells using the same ^18^O exchange assay \[[@R31]\]. Extracellular CA activity of MDA-MB-231 cells was also significantly reduced by 1 μM acetazolamide \[[@R32]\]. The inhibitors VR16-09 and VD11-4-2 exhibited higher effect towards CA IX expressed in cellular models than previously reported compounds likely due to higher affinity.

![*IC~50~* determination of VR16-09, VD11-4-2, and VD12-09 in hypoxic MDA-MB-231 cells and CA IX-dependent mode of action for inhibitors in hypoxic HeLa CA IX KO cells\
(**A**) Original recordings of the log enrichment of MDA-MB-231 cells pre-incubated with VD11-4-2 for up to 3 h. The beginning of each trace shows the rate of degradation of the ^18^O-labeled substrate in the non-catalyzed reaction. (**B**--**D**) -- Relative CA activity in MDA-MB-231 cells, incubated under hypoxia (1% O~2~) for 3 days. Cells were pre-incubated with VR16-09 (B), VD11-4-2 (C), or VD12-09 (D) for up to 3 h. CA activity was determined by MS gas-analysis from the increase in the rate of log enrichment after addition of cell suspension. CA activity in the presence of inhibitor was normalized to the activity in the absence of inhibitor. (**E**) CA activity in HeLa-WT and HeLa-CA IX-KO cells, before (white bars) and after addition of VR16-09, VD11-4-2 or VD12-09 (black bars). Average + SD of 4 independent experiments per cell line are shown. Asterisks indicate significant difference between CA activity before and after addition of inhibitor (^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001, n.s.: not significant).](oncotarget-09-26800-g003){#F3}

The functional activity of inhibitors was further confirmed by measuring the rise in extracellular pH directly inside a hypoxic chamber \[[@R33]\]. VR16-09, VD11-4-2, and VD12-09 significantly (*p \<* 0.05) reduced hypoxia-induced acidification of HeLa cells in a dose-dependent manner, while the effect on cells exposed to normoxia was negligible (Figure [4A](#F4){ref-type="fig"}). This functional activity was the most pronounced for VR16-09 at 50 μM, which significantly reduced hypoxia-induced acidosis of 4 investigated cell lines (Figure [4A, 4B](#F4){ref-type="fig"}). VD11-4-2 also significantly reduced (*p \<* 0.05) hypoxic acidification of HeLa, H460, MDA-MB-231, and A549 cells (Figure [4A, 4C](#F4){ref-type="fig"}). A 4-fold lower concentration of sodium bicarbonate in the medium was used for A549 to determine the functional effects of the compounds due to relatively low levels of hypoxia-induced CA IX ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). VD12-09 exhibited functional activity in HeLa cells (Figure [4A](#F4){ref-type="fig"}). The smallest, albeit significant (*p \<* 0.05), impact on extracellular acidification was found for VR16-10 ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). Interestingly, inhibitors VR16-09 and VR16-10 differ structurally by the size of the hydrophobic ring at *ortho* position. Thus, a 12-carbon ring of VR16-09 was found to be more favorable than an 8-carbon ring of VR16-10 because \~3-fold higher functional effects of VR16-09 on the reduction of hypoxia-induced acidification of H460 cells were observed, even though their affinities towards recombinant CA IX were similar (*K~d~s* of 0.16 and 0.20 nM, respectively). Functional activities of several CA IX-targeting agents, such as fluorescent sulfonamide \[[@R33]\] and nitroimidazole-based inhibitors \[[@R34], [@R35]\] have been previously reported using the same method in HeLa cells, where a dose-dependent reduction in hypoxia-induced extracellular acidification was observed. Results of the current study indicate that the inhibitors investigated here are more efficacious in decreasing extracellular acidification than previously described compounds because of their significant functionality at lower concentrations (5--50 μM), highlighting the potential for CA IX-targeting therapy.

![(**A**) Changes in extracellular acidification of HeLa cells after the treatment with VR16-09, VD11-4-2 or VD12-09 for 72 h under normoxia (21% O~2~; white bars) or hypoxia (0.2% O~2~; grey bars). (**B**--**C**) Effect of VR16-09 (B) and VD11-4-2 (C) on the hypoxia-induced extracellular acidification of H460, MDA-MB-231, A549, and AsPC-1 after the exposure for 72 h. Average ± SD of at least 3 independent experiments is shown. Asterisks indicate significant difference between medium pH of cells exposed to DMSO and cells treated with various doses of inhibitor under hypoxic conditions (^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001, ^\*\*\*\*^*p* \< 0.0001).](oncotarget-09-26800-g004){#F4}

Interestingly, hypoxia-induced acidosis of AsPC-1 cells increased after exposure to VR16-09 or VD11-4-2 (Figure [4B](#F4){ref-type="fig"}, [4C](#F4){ref-type="fig"}), related to the unique expression of monocarboxylate transporter 1 (MCT1) under both normoxic and hypoxic conditions in these cells ([Supplementary Figure 5A](#SD1){ref-type="supplementary-material"}). Recently, CA IX was proposed to be a 'H^+^-distributing antenna' for MCT1 to facilitate rapid extrusion of lactate and H^+^ from the cell \[[@R36]\]. Even though the catalytic activity of CA IX was inhibited in AsPC-1 by compounds, the rise of acidification might be caused by MCT1 which is further non-catalytically stimulated by CA IX. In contrast, MCT4 was expressed in all tested cell lines and was up-regulated in response to hypoxia ([Supplementary Figure 5B](#SD1){ref-type="supplementary-material"}), in line with previously confirmed HIF-1α-dependent mechanism of MCT4 expression in cancer cells \[[@R37]\].

Inhibitor-induced cytotoxicity {#s2_4}
------------------------------

Cytotoxicity of tested compounds was higher in normoxic than hypoxic cell monolayers, as determined by cell viability assay using alamarBlue^®^ after treatment for 48 h or 72 h ([Supplementary Figure 6A, 6B](#SD1){ref-type="supplementary-material"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Inhibitors were less effective in reducing viability of hypoxic CA IX-expressing cells than normoxic cells without or with significantly lower CA IX expression. Sensitivity of HeLa and H460 cells to VR16-10 was the lowest and is in line with the lowest VR16-10 functional activity measured by extracellular pH assay. Therefore, VR16-10 was not investigated further. Similarly, compounds were more effective in reducing clonogenic survival in normoxic compared to hypoxic monolayer HeLa cells ([Supplementary Figure 6C](#SD1){ref-type="supplementary-material"}). Our results correlate with previously published cytotoxicity profiles of benzenesulfonamides, including SLC-0111 \[[@R38]\], sulfamate S4 \[[@R39]\], and dual-target compounds bearing various CA IX-targeting moieties combined with different anti-cancer drugs \[[@R40]\], which showed more effective cell kill in normoxia than hypoxia. We hypothesize that higher cytotoxicity of inhibitors in normoxic cells as compared with hypoxic cells could be due to the affinity of investigated compounds towards CA XII, expressed in all cell lines investigated here and shown to be up-regulated to compensate the CA IX knockdown \[[@R41]\]. Thus, new cellular models with both CA IX and CA XII KO would be crucial to determine the link between functional activity of compounds and CA IX or CA XII-dependent cellular mechanisms.

Hypoxia-dependent effect on spheroid clonogenic survival {#s2_5}
--------------------------------------------------------

To confirm the CA IX-dependent efficacy of the compounds, H460 spheroids were employed. Immunofluorescence analysis confirmed overlap between CA IX expression and pimonidazole (PIMO)-positive hypoxia in sections of H460 spheroids grown for 11 days, whereas neither CA IX nor hypoxia were found in spheroids grown for 7 days (Figure [5A](#F5){ref-type="fig"}). Therefore, non-hypoxic (4 days) and hypoxic (11 days) H460 spheroids were exposed to VR16-09 using an effective dose based on extracellular pH assays (Figure [4A, 4B](#F4){ref-type="fig"}) for 24 h and afterwards plated for clonogenic survival. In contrast to 2D cell viability and clonogenic survival assays, a hypoxia-dependent effect on clonogenic survival of VR16-09 was found in H460 spheroids (Figure [5B](#F5){ref-type="fig"}). The 3D cell models reflect important properties of *in vivo* tumors such as interactions between cells, oxygen gradients, penetration of drugs, response and resistance, and production/deposition of extracellular matrix, which are absent in rapidly and uncontrollably growing 2D cells \[[@R42]--[@R44]\]. Our study confirms the importance of using *in vitro* 3D cellular models for screening of CA IX-targeting inhibitors.

![(**A**) Immunofluorescence images of H460 spheroids stained for DAPI (blue), PIMO (green) and CA IX (red). The scale bar indicates 100 μM. (**B**) Survival of clonogenic cells derived from non-hypoxic (■) and hypoxic (□) H460 spheroids exposed to VR16-09 for 24 h on day 4 or day 11, respectively. Asterisks indicate statistically significant differences between the surviving fractions of clonogenic cells derived from normoxic or hypoxic spheroids after exposure to the same dose (^\*^*p* \< 0.05, ^\*\*\*^*p* \< 0.001).](oncotarget-09-26800-g005){#F5}

MATERIALS AND METHODS {#s3}
=====================

Chemistry {#s3_1}
---------

VR16-09 and VR16-10 were synthesized following a similar route as described in our previous research \[[@R24]\]. Pentafluorobenzenesulfonyl chloride (1, Acros Organics) was converted to pentafluorobenzenesulfonamide (2) via amination with aqueous ammonia (scheme [1](#F6){ref-type="fig"}) by our improved method \[[@R25]\]. On the basis of our previous investigations, sulfonamide 2 undergoes aromatic nucleophilic substitution reactions with sulfur-centered nucleophiles readily and forms exclusively the *para*-substituted products. High reactivity of polyfluorinated compounds leads to the formation of monosubstituted or even further substituted compounds. The subsequent *ortho*-substitution occurs in the case of 4-substituted-2,3,5,6-tetrafluobenzenesulfonamides, bearing non-oxidized sulfur-centered substitutes at *para* position. Similarly, sulfonamide 2 was treated with 4-(2-mercaptoethyl)benzoic acid (7) to furnish *para*-substituted compound 3 and subsequent aromatic nucleophilic substitution reactions with cyclododecylamine and cyclooctylamine in DMSO in the presence of Et~3~N yielded desirable compounds VR16-09 and VR16-10. Since suitable sulfur-centered nucleophile 7 was not commercially available, it was synthesized using literature methods. Starting from commercially available (2-bromoethyl)benzene (4, Acros Organics), Friedel-Crafts acylation with acetyl chloride proceeded in high yield. Acylation was accomplished as described in literature \[[@R45]\], except for changing highly toxic solvent carbon disulfide to more acceptable dichloromethane. Conversion of methyl ketone 5 into benzoic acid 6 was carried out via haloform reaction by the method of Foreman and McElvain \[[@R46]\]. Finally, benzoic acid 6 was treated with thiourea in refluxing water to generate intermediate salt, which was partitioned by adding sodium hydroxide solution as described by Takano \[[@R47]\].

Compound characterization {#s3_2}
-------------------------

All starting materials and reagents were commercial products. They were used without further purification. Melting points of the compounds were determined in open capillaries on a Thermo Scientific 9100 Series and are uncorrected. ^1^H and ^13^C NMR spectra were recorded on a Bruker spectrometer (400 and 100 MHz, respectively) in DMSO-d~6~ using residual DMSO signals (2.52 ppm and 40.21 ppm for ^1^H and ^13^C NMR spectra, respectively) as internal standard. ^19^F NMR spectra were recorded on a Bruker spectrometer (376 MHz) with CFCl~3~ as an internal standard. Proton, carbon and fluorine chemical shifts were expressed in parts per million (ppm) in the indicated solvent. Multiplicity was defined as s (singlet), d (doublet), t (triplet), q (quartet), dd (a doublet of doublets), ddd (a doublet of doublet of doublets), m (multiplet), br s (broad singlet). TLC was performed with silica gel 60 F~254~ aluminum plates (Merck) and visualized with UV light. Column chromatography was performed using silica gel 60 (0.040--0.063 mm, Merck). High-resolution mass spectra (HRMS) were recorded on a Dual-ESI Q-TOF 6520 mass spectrometer (Agilent Technologies). The purity of final compounds was verified by HPLC to be \>95% using the Agilent 1290 Infinity instrument with a Poroshell 120 SB-C18 (2.1 mm × 100 mm, 2.7 μm) reversed-phase column.

Pentafluorobenzenesulfonamide (2) {#s3_3}
---------------------------------

The solution of pentafluorobenzenesulfonyl chloride (1) (1.00 g, 3.75 mmol) and THF (60 mL) was cooled to \~ --10° C and aqueous ammonia (\~1.20 mL, 25 %) was added dropwise while stirring until the solution was at pH \~7. After stirring for an additional 1 h, the solvent was removed under reduced pressure and the white solid was washed with cold H~2~O. Recrystallization was accomplished from H~2~O. Yield: 0.84 g (90 %), mp 156--157° C close to the value in the literature, mp 156° C \[[@R48]\]. ^1^H NMR (400 MHz, DMSO-*d~6~*): 8.48 (2H, s, SO~2~NH~2~). ^19^F NMR (376 MHz, DMSO-*d~6~*): --139.5 (2F, dd, *^1^J* = 19 Hz, *^2^J* = 6 Hz), --149.39 (1F, t, *J* = 22 Hz), --161.03 (2F, t, *J* = 20 Hz).

4-(2-{\[4-(Aminosulfonyl)-2,3,5,6-tetrafluorophenyl\]thio}ethyl)benzoic acid (3) {#s3_4}
--------------------------------------------------------------------------------

![](oncotarget-09-26800-i005.jpg)

The mixture of pentafluorobenzenesulfonamide (2) (2.00 g, 8.09 mmol), 4-(2-mercaptoethyl)benzoic acid (7) (1.77 g, 9.71 mmol), Et~3~N (2.50 mL, 17.9 mmol), and MeOH (20 mL) was stirred at ambient temperature for 24 h. The solution was acidified to pH = 5 with conc. HCl and MeOH was removed under reduced pressure. The white solid was washed with water and dried. Recrystallization was accomplished from EtOH. Yield: 2.42 g (73 %), mp 235--236° C. ^1^H NMR (DMSO-*d~6~*, 400 MHz) δ 12.87 (1H, br s, COOH), 8.40 (2H, s, SO~2~NH~2~), 7.85 (2H, d, *J* = 8.1 Hz, ArH), 7.36 (2H, d, *J* = 8.1 Hz, ArH), 3.36 (2H, t, *J* = 7.3 Hz, S[CH]{.ul}~2~CH~2~), 2.95 (2H, t, *J* = 7.3 Hz, SCH~2~[CH]{.ul}~2~). ^13^C NMR (DMSO-*d~6~*, 100 MHz) δ 167.57 (CO), 146.85 (C3, C5, dd, *^1^J* (^19^F-^13^C) = 244.2 Hz, *^2^J* (^19^F-^13^C) = 17.1 Hz), 142.99 (C2, C6, dd, *^1^J* (^19^F-^13^C) = 254.0 Hz, *^2^J* (^19^F-^13^C) = 17.1 Hz), 144.79 (Ar), 129.78 (Ar), 129.53 (Ar), 129.28 (Ar), 122.92 (C4, t, *J* (^19^F-^13^C) = 15.3 Hz), 118.64 (C1, t, *J* (^19^F-^13^C) = 20.4 Hz), 35.91 (SCH~2~[CH~2~]{.ul}), 34.79 (S[CH~2~]{.ul}CH~2~). ^19^F NMR (DMSO-*d~6~*, 376 MHz) δ: --133.0 (2F, dd, *^1^J* = 24.3 Hz, *^2^J* = 9.9 Hz), --139.1 (2F, dd, *^1^J* = 24.2 Hz, *^2^J* = 9.9 Hz). HRMS for C~15~H~11~F~4~NO~4~S~2~ \[(M-H)^-^\]: calcd. 407.9993, found 407.9986.

4-(2-{\[4-(Aminosulfonyl)-3-(cyclododecylamino)-2,5,6-tetrafluorophenyl\]thio}ethyl)benzoic acid (VR16-09) {#s3_5}
----------------------------------------------------------------------------------------------------------

![](oncotarget-09-26800-i006.jpg)

The mixture of 4-(2-{\[4-(aminosulfonyl)-2,3,5,6-tetrafluorophenyl\]thio}ethyl)benzoic acid (3) (0.40 g, 0.98 mmol), cyclododecylamine (0.286 g, 1.56 mmol), Et~3~N (0.34 mL, 2.44 mmol), and DMSO (6 mL) was stirred at 70° C for 36 h. The solution was cooled to room temperature, diluted with water (20 mL) and acidified to pH = 5 with 2 M HCl. The white solid was filtered, washed with water and dried. Recrystallization was accomplished from EtOH:H~2~O (2:1). Yield: 0.36 g (64 %), mp 169--170° C. ^1^H NMR (DMSO-*d~6~*, 400 MHz) δ 12.86 (1H, br s, COOH), 8.13 (2H, s, SO~2~NH~2~), 7.85 (2H, d, *J* = 8.1 Hz, ArH), 7.33 (2H, d, *J* = 8.1 Hz, ArH), 6.19 (1H, d, *J* = 9.2 Hz, NH), 3.69 (1H, br s (unresolved m), CH of cyclododecane), 3.28 (2H, t, *J* = 7.3 Hz, S[CH~2~]{.ul}CH~2~), 2.91 (2H, t, *J* = 7.3 Hz, SCH~2~[CH~2~]{.ul}), 1.8-1.1 (22H, m, cyclododecane). ^13^C NMR (DMSO-*d~6~*, 100 MHz) δ 167.63 (CO), 148.18 (C3, d, *J* (^19^F-^13^C) = 244 Hz), 144.84 (C6, ddd, *^1^J* (^19^F-^13^C) = 249.6 Hz, *^2^J* (^19^F-^13^C) = 15.6 Hz), *^3^J* (^19^F-^13^C) = 3.6 Hz), 144.86 (Ar), 141.62 (C5, ddd, *^1^J* (^19^F-^13^C) = 236.5 Hz, *^2^J* (^19^F-^13^C) = 15.3 Hz, *^3^J* (^19^F-^13^C) = 4.6 Hz), 132.81 (C2, d, *J* (^19^F-^13^C) = 15.1Hz), 129.78 (Ar), 129.57 (Ar), 129.14 (Ar), 119.53 (C1, dd, *^1^J* (^19^F-^13^C) = 11.9 Hz, *^2^J* (^19^F-^13^C) = 4.5 Hz), 117.52 (C4, dd, *^1^J* (^19^F-^13^C) = 23.8 Hz, *^2^J* (^19^F-^13^C) = 19.1 Hz), 52.68 (CH of cyclododecane, d, *J* = 10.6 Hz), 35.85 (SCH~2~[CH~2~]{.ul}), 34.73 (S[CH~2~]{.ul}CH~2~), 30.95 (cyclododecane), 24.10 (cyclododecane), 23.75 (cyclododecane), 23.40 (cyclododecane), 23.23 (cyclododecane), 21.28 (cyclo dodecane). ^19^F (DMSO-*d~6~*, 376 MHz) δ --120.6 (C3-F, d, *J* = 11.3 Hz), --137.0 (C5-F, dd, *^1^J* = 27 Hz, *^2^J* = 11.5 Hz), --145.1 (C6-F, dd, *^1^J* = 27 Hz, *^2^J* = 2.5 Hz). HRMS for C~27~H~35~F~3~N~2~O~4~S~2~ \[(M-H)^-^\]: calcd. 571.1918, found 571.1924.

4-(2-{\[4-(Aminosulfonyl)-3-(cyclooctylamino)-2,5,6-tetrafluorophenyl\]thio}ethyl)benzoic acid (VR16-10) {#s3_6}
--------------------------------------------------------------------------------------------------------

![](oncotarget-09-26800-i007.jpg)

The mixture of 4-(2-{\[4-(aminosulfonyl)-2,3,5,6-tetrafluorophenyl\]thio}ethyl)benzoic acid (3) (0.40 g, 0.98 mmol), cyclooctylamine (0.214 mL, 1.56 mmol), Et~3~N (0.34 mL, 2.44 mmol), and DMSO (6 mL) was stirred at 70° C for 24 h. The solution was cooled to room temperature, diluted with water (20 mL) and acidified to pH = 5 with 2 M HCl. The white solid was filtered, washed with water and dried. Recrystallization was accomplished from EtOH:H~2~O (2:1). Yield: 0.32 g (64 %), mp 166--168° C. ^1^H NMR (DMSO-*d~6~*, 400 MHz) δ 12.87 (1H, br s, COOH), 8.11 (2H, s, SO~2~NH~2~), 7.85 (2H, d, *J* = 8.1 Hz, ArH), 7.33 (2H, d, *J* = 8.1 Hz, ArH), 6.33 (1H, d, *J* = 8.7 Hz, NH), 3.71 (1H, br s (unresolved m), CH of cyclooctane), 3.30 (2H, t, *J* = 7.3 Hz, S[CH]{.ul}~2~CH~2~), 2.91 (2H, t, *J* = 7.3 Hz, SCH~2~[CH~2~]{.ul}), 1.9-1.4 (14H, m, cyclooctane). ^13^C NMR (DMSO-*d~6~*, 100 MHz) δ 167.64 (CO), 148.16 (C3, d, *J* (^19^F-^13^C) = 242.7 Hz), 144.84 (C6, ddd, *^1^J* (^19^F-^13^C) = 249.7 Hz, *^2^J* (^19^F-^13^C) = 15.7 Hz, *^3^J* (^19^F-^13^C) = 3.8 Hz), 144.9 (Ar), 141.62 (C5, ddd, *^1^J* (^19^F-^13^C) = 236.0 Hz, *^2^J* (^19^F-^13^C) = 15.1 Hz, *^3^J* (^19^F-^13^C) = 4.4 Hz), 132.21 (C2, d, *J* (^19^F-^13^C) =14.1 Hz), 129.81 (Ar), 129.53 (Ar), 129.21 (Ar), 119.41 (C1, dd, *^1^J* (^19^F-^13^C) = 11.5 Hz, *^2^J* (^19^F-^13^C) = 4.9 Hz), 117.51 (C4, dd, *^1^J* (^19^F-^13^C) = 23.7 Hz, *^2^J* (^19^F-^13^C) = 18.5 Hz), 55.66 (CH of cyclooctane, d, *J* = 11.4 Hz), 35.86 (SCH~2~[CH~2~]{.ul}), 34.63 (S[CH~2~]{.ul}CH~2~), 32.62 (cyclooctane), 27.29 (cyclooctane), 25.94 (cyclooctane), 25.53 (cyclooctane), 23.38 (cyclooctane). ^19^F NMR (DMSO-*d~6~*, 376MHz) δ --120.81 (C3-F, dd, *^1^J* = 11.4 Hz, *^2^J* = 3.1 Hz), --137.1 (C5-F, dd, *^1^J* = 27.0 Hz, *^2^J* = 11.5 Hz), --145.2 (C6-F, dd, *^1^J* = 26.9 Hz, *^2^J* = 3.0 Hz). HRMS for C~23~H~27~F~3~N~2~O~4~S~2~ \[(M-H)^-^\]: calcd. 515.1292, found 515.1284.

1-\[4-(2-Bromoethyl)phenyl\]ethanone (5) {#s3_7}
----------------------------------------

A mixture of AlCl~3~ (2.91 g, 21.82 mmol), acetyl chloride (1.71 mL, 24.05 mmol) and CH~2~Cl~2~ (50 mL) was stirred at 0° C -- +5° C until AlCl~3~ dissolved. Solution of (2-bromoethyl)benzene (4) (2.00 mL, 14.64 mmol) in acetyl chloride (3.4 mL) was then added dropwise at 0° C -- +2° C. The resulting mixture was stirred at 0° C -- +2° C for 1h and then poured into a mixture of concentrated HCl (20 mL) and ice (200 mL). This mixture was extracted with CH~2~Cl~2~ (30 mL × 3). The combined organic extracts were washed with 1N NaOH, water and brine, dried over Na~2~SO~4~ and concentrated under reduced pressure. The resultant residue was subjected to flash chromatography (silica gel, hexane/EtOAc, 9:1) to afford compound 5 (2.83 g, 85 %) as an oil. ^1^H NMR (400 MHz, DMSO*-d~6~*) δ 7.94 (2H, d, *J* = 8.2 Hz, ArH), 7.33 (2H, d, *J* = 8.2 Hz, ArH), 3.61 (2H, t, *J* = 7.3 Hz, CH~2~), 3.24 (2H, t, *J* = 7.3 Hz, CH~2~), 2.60 (3H, s, COCH~3~).

4-(2-Bromoethyl)benzoic acid (6) {#s3_8}
--------------------------------

A solution of sodium hydroxide (4.16 g, 104 mmol) in H~2~O/dioxane (50 mL/40 mL) was prepared in three-necked, round bottomed flask fitted with a thermometer and a dropping funnel. The solution was cooled to 0° C in an ice-salt bath, and bromine (2.04 mL, 39.6 mmol) was slowly added with stirring at 0° C -- +7° C. 1-\[4-(2-Bromoethyl)phenyl\]ethanone (5) (3.00 g, 13.2 mmol) was then added dropwise to sodium hypobromite solution at 0° C -- +2° C. The resulting mixture was stirred at 0° C -- +5° C for 1.5 h and then acidified with concentrated HCl. The precipitated acid was filtered, washed with water and dried. Recrystallization was accomplished from toluene. Yield: 2.50 g (83 %), mp 207--208° C, close to the value in the literature mp 205--207° C \[[@R46]\]. ^1^H NMR (400 MHz, DMSO*-d~6~*) δ 12.91 (1H, br s, COOH), 7.89 (2H, d, *J* = 8.3 Hz, ArH), 7.41 (2H, d, *J* = 8.4 Hz, ArH), 3.78 (2H, t, *J* = 7.1 Hz, CH~2~), 3.21 (2H, t, *J* = 7.1 Hz, CH~2~).

4-(2-Mercaptoethyl)benzoic acid (7) {#s3_9}
-----------------------------------

The mixture of 4-(2-bromoethyl)benzoic acid (6) (2.00 g, 8.73 mmol), thiourea (0.80 g, 10.43 mmol), H~2~O (20 mL) was refluxed for 3 h. The solution was cooled to room temperature and 10 % (w/v) aqueous NaOH (18 mL) was added and the mixture was refluxed again for 1h. The solution was then cooled to room temperature, acidified to pH = 5 with 2 M HCl and filtered. The white solid was washed with water and dried. Recrystallization was accomplished from EtOH. Yield: 1.47 g (92 %), mp 157--159° C, close to the value in the literature mp 156--158° C \[[@R47]\]. ^1^H NMR (400 MHz, DMSO*-d~6~*) δ 12.85 (1H, br s, COOH), 7.88 (2H, d, *J* = 8.2 Hz, ArH), 7.36 (2H, d, *J* = 8.2 Hz, ArH), 2.92 (2H, t, *J* = 7.4 Hz, CH~2~), 2.77 (2H, q, *J* = 6.8 Hz, CH~2~), 2.30 (1H, t, *J* = 7.7 Hz, SH).

CA inhibition assay {#s3_10}
-------------------

The enzymatic activity of carbonic anhydrase isoforms and their inhibition was determined by the stopped-flow CO~2~ hydration assay where the formed acid was followed by the absorbance change of a pH indicator. The Applied Photophysics SX.18MV-R stopped-flow spectrometer was used to measure the absorbance change of Phenol-Red pH indicator at 557 nm \[[@R49]\]. Saturated CO~2~ solution was prepared by bubbling the CO~2~ gas in MilliQ water at 25° C for 1 h. Experiments were performed at 25° C using 25 mM Hepes buffer containing 50 mM NaCl (pH 7.5), 0--10 μM compound with the final 0.4% (v/v) DMSO concentration. The final enzyme concentration was 10 nM for CA IX and 20 nM for CA XII. Raw curves of absorbance change were analyzed using Origin 8.1 (OriginLab Corporation) and the slope values were used to evaluate the rates of CO~2~ hydration. Spontaneous CO~2~ hydration rate was used as a zero value, while the CA catalyzed reaction rate - as a maximum value. The *K~d~* values were determined using the Morrison equation \[[@R50]\]: $$\text{CA act}.(\%) = \left( {1 - \frac{(\lbrack\text{CA}\rbrack + \lbrack\text{I}\rbrack + K_{d}) - \sqrt{{(\lbrack\text{CA}\rbrack + \lbrack\text{I}\rbrack + K_{d})}^{2} - 4\lbrack\text{CA}\rbrack\lbrack\text{I}\rbrack}}{2\lbrack\text{CA}\rbrack}} \right)100\%$$

Fluorescent thermal shift assay {#s3_11}
-------------------------------

The binding affinity of synthesized compounds to recombinant human CAs was measured by the fluorescent thermal shift assay (FTSA) where the thermal stabilization of the protein by the compound was determined by following the fluorescence dependence on temperature at various added compound concentrations. The melting temperature (*T~m~*) of CA was measured using the Corbett Rotor-Gene 6000 instrument (QIAGEN Rotor-Gene Q, excitation at 365 ± 20 nm, emission detection at 460 ± 15 nm). The protein was heated from 25 to 99° C at a rate of 1° C/min and the fluorescence change of the solvatochromic dye 8-anilino-1-naphthalene sulfonate (ANS) was followed. The samples consisted of 5--10 μM CA, 0--200 μM ligand, 50 μM ANS, and 50 mM sodium phosphate buffer containing 100 mM NaCl at pH 7.0, with the final DMSO concentration of 2% (v/v). Protein unfolding profiles and the melting temperatures were determined at each ligand concentration while recording extrinsic fluorescence of ANS. Data analysis was performed as previously described \[[@R51]\]. All experiments were repeated at least twice.

CA IX purification, crystallization and X-ray crystallography data collection {#s3_12}
-----------------------------------------------------------------------------

Protein was prepared and crystalized as described previously \[[@R30]\]. Data were collected at beamline BL14.1, Helmholtz-Zentrum Berlin, in Berlin, Germany. Images were processed by MOSFLM \[[@R52]\] and reflections scaled by SCALA \[[@R53]\]. The structure was determined by molecular replacement in MOLREP \[[@R54]\]. The ligand parameter files were generated by LIBCHECK \[[@R55]\]. Ligand modeling and manual refinement of the structure were done in COOT, followed by refinement in REFMAC. Data processing, refinement, and validation statistics are shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Cell culture {#s3_13}
------------

Human cervical (HeLa), lung (H460, A549), breast (MDA-MB-231), and pancreatic (AsPC-1) cancer cells were cultured in Dulbecco\'s Modified Eagle\'s Medium (DMEM, Lonza) supplemented with 10% fetal bovine serum (FBS, Lonza). Cells were exposed to hypoxic conditions in the hypoxic chamber (MACS VA500 microaerophilic workstation, Don Whitley Scientific, UK) with 0.2% O~2~, 5% CO~2~ and residual N~2~. Simultaneously, normoxic cells were grown in the humidified incubator with 21% O~2~, 5% CO~2~ at 37° C.

Generating HeLa CA IX knockout cells {#s3_14}
------------------------------------

HeLa CA IX knockout (KO) clones were established as described elsewhere \[[@R56]\]. HeLa cells were routinely cultured in DMEM (Lonza) supplemented with 10% FBS (Lonza) and transfected with a vector containing a CA IX-CRISPR guide RNA (CACCGGGGAATCCTCCTGCATCCG) using linear polyethylenimine (P-PEI, Polysciences Inc.). 24 h after transfection, selection with puromycin was started and maintained for 48 h, after which monoclones were picked and routinely cultured. After exposure to hypoxia (0.2%, 24 h), an initial screening for CA IX expression was performed by Western blotting ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}), followed by genetic confirmation of CA IX KO in clones that showed no CA IX expression. This was done by single allele sequencing using the TOPO^®^ TA Cloning^®^ Kit (Invitrogen) according to the manufacturer\'s protocol. KO-causing mutations in the *CA9* gene were confirmed in two alleles per clone.

Determination of CA catalytic activity in cancer cells via gas-analysis mass spectrometry {#s3_15}
-----------------------------------------------------------------------------------------

Catalytic activity of CA in hypoxic MDA-MB-231 and HeLa cancer cells was determined by monitoring the ^18^O depletion of doubly labeled ^13^C^18^O~2~ through several hydration and dehydration steps of CO~2~ and HCO~3~^-^ at 24° C \[[@R57], [@R58]\]. The reaction sequence of ^18^O loss from ^13^C^18^O^18^O (m/z = 49) over the intermediate product ^13^C^18^O^16^O (m/z = 47) and the end product ^13^C^16^O^16^O (m/z = 45) was monitored with a quadrupole mass spectrometer (OmniStar GSD 320; Pfeiffer Vacuum, Asslar, Germany). The relative ^18^O enrichment was calculated from the measured 45, 47, and 49 m/z abundance as a function of time according to: log enrichment = log (49×100/(49+47+45)). For the calculation of CA activity, the rate of ^18^O depletion was obtained from the linear slope of the log enrichment over the time, using OriginPro 8.6 (OriginLab Corporation). The rate was compared with the corresponding rate of the non-catalyzed reaction. Enzyme activity in units (U) was calculated from these two values as defined by Badger and Price \[[@R59]\]. From this definition, one unit corresponds to 100% stimulation of the non-catalyzed ^18^O depletion of doubly labeled ^13^C^18^O~2~. MDA-MB-231 cells were cultured in Gibco Leibovitz-L15 medium (Life Technologies GmbH, Darmstadt, Germany), supplemented with 10% fetal calf serum, 5 mM glucose and 1% penicillin/streptomycin, pH 7.4. HeLa cells were cultured in RPMI-1640 Medium (Sigma Aldrich, Schnelldorf, Germany), supplemented with 10% fetal calf serum and 1% penicillin / streptomycin. Both cell lines were cultured under hypoxia (1% O~2~) for 3 days prior to measurements. Cells were trypsinized, washed and resuspended in HEPES-buffered saline (143 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 1 mM MgSO~4~, 1 mM Na~2~HPO~4~, 10 mM HEPES, pH 7.2). For determination of *IC~50~* values, 2 cell culture plates (58 cm^2^), grown to 80% confluency, were used for every single measurement. To ensure an equal amount of cells within one set of measurements, cells from several plates were pooled and then aliquoted according to the number of tested inhibitor concentrations. For the determination of *IC~50~*, the cell suspensions were incubated in the corresponding concentration of inhibitor for up to 3 h. For every measurement, the non-catalyzed reaction was determined for 6 min in the presence of inhibitor, before cell suspension was added to the measuring cuvette and the catalyzed reaction was determined for 8 min. CA activity in the presence of inhibitor was normalized to the activity in the absence of inhibitor. *IC~50~* values were determined by Hill equation using OriginPro 8.6. To investigate specificity of the inhibitors in HeLa WT and HeLa CA IX KO cells, the non-catalyzed reaction was determined for 6 min in the absence of inhibitor, before a suspension of 5 × 10^6^ cells was added to the measuring cuvette. After the catalyzed reaction was determined for 6 min, the inhibitor was added to the cuvette and the reaction was determined for another 6 min.

Extracellular acidification (pH) assay {#s3_16}
--------------------------------------

HeLa, H460, MDA-MB-231, and AsPC-1 cells were cultured in DMEM (Lonza) supplemented with 10% FBS (Lonza), whereas A549 cells were grown in-house made analogous medium differing only by a lower amount of sodium bicarbonate (final concentration 10 mM). Cell densities for each cell line were optimized to get \~100% confluence at the end of experiment under normoxic and hypoxic (0.2% O~2~) conditions upon vehicle (0.05% DMSO) treatment. Such conditions were necessary to obtain the highest possible level of CA IX-dependent extracellular acidification. Cells were plated in 6 cm dishes and allowed to attach overnight in normoxia. The next day cells were exposed to 5--50 μM doses of each inhibitor or DMSO for 72 h in parallel under normoxic or hypoxic conditions and pH of the culture medium was measured at the end of each experiment as previously reported \[[@R33]\]. Results are shown as a difference between the pH of medium in the control plate (without seeded cells) and the pH of medium in the targeted plate (cells exposed to the compound or vehicle).

Cell viability assay {#s3_17}
--------------------

Cytotoxicity of inhibitors was determined by the alamarBlue^®^ cell viability assay (Life Technologies). Cell densities for HeLa, H460, MDA-MB-231, A549, and AsPC1 were optimized to get \~80% confluence at the end of experiment under normoxic and hypoxic (0.2% O~2~) conditions upon vehicle (0.25% DMSO) treatment. Briefly, cells were seeded in 96-well plates and allowed to attach overnight in normoxia. On the next day, cells were exposed to normoxia or hypoxia and medium was replaced with pre-incubated normoxic or hypoxic medium with final concentrations of 10--150 μM of inhibitor or DMSO. After 72 h, cells were incubated with 10% alamarBlue^®^ for 2 h under normoxia at 37° C. The fluorescence signal was measured using the multi-mode microplate reader (FLUOstar^®^ Omega, BMG Labtech) at 580 nm (excitation wavelength 540 nm). Response to treatments was quantified by evaluating *EC~50~* values (concentration of inhibitor that leads to half-maximum viability response determined by Hill fit).

Clonogenic cell survival assays {#s3_18}
-------------------------------

Clonogenic survival of HeLa cell monolayers was evaluated using cell densities applied in the extracellular acidification assay to determine the effect of inhibitors on the clonogenic cell survival while having the same acidification conditions. Cells were exposed to 10--50 μM VR16-09, VD11-4-2, VD12-09, or 0.25% DMSO for 72 h upon normoxic or hypoxic conditions (0.2% O~2~). Such doses of inhibitors significantly reduced hypoxia-induced acidification. Then cells were trypsinized, reseeded in triplicate with known cell densities and allowed to form colonies for 14 days. To test inhibitors in 3D cell models, non-hypoxic and hypoxic H460 spheroids were exposed to 5--15 μM doses of VR16-09 or 0.25% DMSO for 24 h on day 4 or day 11, respectively. Single cell suspensions were prepared and cells were plated in triplicate with known cell densities and allowed to form colonies for 14 days. Colonies were quantified after staining and fixation with 0.4% methylene blue in 70% ethanol. Surviving fraction was normalized to vehicle (DMSO).

Spheroid growth {#s3_19}
---------------

To prepare plates for the growth of attachment-free H460 spheroids, autoclaved 1.5% w/v agarose (Sigma-Aldrich) was dispensed in the inner 60 wells of 96-well plates (50 μL/well) and left for polymerization at room temperature for 30 min. H460 cells were plated in modified 96-well plates to the surface of agarose menisci with a density of 500 cells/well. The DMEM was refreshed every two days. After 7 or 11 days in culture, spheroids were incubated with 20 μg/mL pimonidazole (PIMO, Hypoxyprobe-1, HP-1000, BioConnect) for 2 h at 37° C, collected and cryoconserved for immunofluorescence analysis (see below). In parallel 4 or 11 days after cell seeding, spheroids of homogeneous volume were treated with 5--15 μM VR16-09 or 0.25% DMSO for 24 h and collected for clonogenic survival assay.

Western blot {#s3_20}
------------

Protein isolates were prepared by incubating scraped cells in RIPA buffer on ice for 30 min, followed by centrifugation to remove cell debris. Protein concentrations were determined using Bradford protein quantification reagent (BioRad). Western blot was performed using primary antibodies, including mouse anti-CA IX (M75, 1:40, kindly provided by Silvia Pastorekova, Institute of Virology, Slovak Academy of Science, Slovak Republic), mouse anti-CA XII (clone 15A4, 1:100, kindly provided by Aurelija Žvirblienė, Institute of Biotechnology, Vilnius University, Lithuania), rabbit anti-MCT1 (1:100), rabbit anti-MCT4 (1:400, kindly provided by Holger M. Becker, University of Veterinary Medicine Hannover, Hannover, Germany), rabbit anti-lamin A (1:10.000, Sigma-Aldrich), and mouse anti-actin (1:2.000.000, MP Biomedicals). Primary antibodies were incubated overnight at 4° C, whereas horseradish peroxidase-linked secondary antibodies (1:2.000, Cell Signaling) were incubated for 1 h at room temperature. Amersham ECL Western Blotting Detection Reagent (GE Healthcare Life Sciences) was applied for the detection of CA XII, MCT1, MCT4, and lamin A, while SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Life Technologies) was used for the visualization of CA IX and actin.

Immunofluorescence analysis {#s3_21}
---------------------------

H460 spheroids of day 7 and day 11 were cryoconserved. Frozen sections (7 μm) of spheroids were fixed in acetone (4° C, 10 min), air-dried and rehydrated in phosphate buffered saline (PBS). Non-specific binding was blocked by incubation with 0.5% goat serum in PBS for 30 min at room temperature. Sections were stained (37° C, 1 h) using primary rabbit anti-PIMO (1:250) or mouse anti-CA IX (1:100, M75), followed by incubation (37° C, 1 h) with secondary goat anti-rabbit Alexa488 or goat anti-mouse Alexa594, respectively (both 1:500, from Invitrogen). Nuclei were stained with DAPI (final concentration 5 μg/mL) for 2 min at room temperature. Staining without primary antibody was used as negative control. Sections were viewed at 10× magnification by Nikon Eclipse E800 microscope (Nikon Instruments Inc.).

Statistics {#s3_22}
----------

Statistical analysis was performed using GraphPad Prism (version 6.01). A non-parametric Mann-Whitney *U* test for small groups was applied to evaluate the statistical significance of differences between two independent groups of variables and *p \<* 0.05 was assumed to be significant (^\*^*p \<* 0.05; ^\*\*^*p \<* 0.01, ^\*\*\*^*p \<* 0.001, ^\*\*\*\*^*p \<* 0.0001).

CONCLUSIONS {#s4}
===========

In conclusion, the integrative set of synthesis, inhibitory activities, biophysical binding profiles, crystallographic analysis, and effects in 2D and 3D cancer cell culture models is described in the present study. X-ray analysis demonstrated novel, previously unseen conformational changes in CA IX active site due to ligand binding. Our compounds exhibited high affinity and selectivity towards recombinant CA IX, reached nanomolar CA IX-dependent functional effects as well reduced hypoxia-induced acidification in a variety of cancer cell lines. Interestingly, hypoxia-dependent reduction of clonogenic survival was only observed in spheroids, highlighting the importance of investigating CA IX-targeting compounds in 3D cell models resembling the naturally occurring hypoxic microenvironment with clonogenic survival as endpoint. The newly designed compounds are therefore promising agents for CA IX-specific therapy.
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